Latest News & Features
Americas
En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA. 23 January 2024
Biotechnology
The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals. 18 January 2024
Biotechnology
Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal. 18 January 2024
Americas
Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms. 16 January 2024
Big Pharma
US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval. 16 January 2024
Big Pharma
Case concerns a supplementary protection certificate granted to Gilead by Finland’s Patent Office for a HIV drug |CJEU judges contradict AG opinion on whether a Finnish regime is at odds with an EU directive. 11 January 2024
Biotechnology
SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions. 11 January 2024
Generics
Judge says Bayer racked up high costs ‘in pursuit of vague point of principle’ | Teva and others wanted presentation slides as part of patent invalidity suit. 9 January 2024
Big Pharma
Generics companies have often inveighed against the “arbitrary and capricious” rule | Judicial immunity granted to Vidal’s decisions at odds with Congress and SCOTUS precedent, say generics and big tech. 9 January 2024
Big Pharma
Dispute hinges on clauses set out in decade-old settlement and licensing agreement | Federal Circuit unpersuaded by arguments suggesting that a federal court erred in denying a preliminary injunction. 4 January 2024